Admissions
Admissions
Facebook-square Instagram Youtube Tiktok

Faculty Member >

Chalirmporn Atasilp, Ph.D.

Publication
Profile Links :

Publication Profile Links :

  • google scholar

Chalirmporn Atasilp, Ph.D.

เฉลิมพร อรรถศิลป์

Asst. Prof. / ผู้ช่วยศาสตราจารย์ ดร.

: atasilp8@tu.ac.th

: CV file

Education :

  • B.Sc. (Medical Technology), Thammasat University
  • Ph.D. (Clinical Pathology), Mahidol University

AWARDS :

  • “Outstanding Teaching Award” two years in a row (2017-2018) at the Faculty of Medical Technology, Rangsit University, Thailand
  • (3rd poster presentation award) “Analysis of UGT1A1 polymorphisms in Thai population by pyrosequencing” Medical Technology Student’s Special Project 2018, Role: Major Advisor
  • (Outstanding Award Oral Presentation) “The association between UGT1A1 and SLCO1B1 polymorphisms and hyperbilirubinemia in Thai neonates”; The first meeting of CICM supervision 2022, Role: Major Advisor
  • (Outstanding Award Poster Presentation) “Influence of DPYD gene polymorphisms on 5-Fluorouracil toxicities in Thai colorectal cancer patients”; The first meeting of CICM supervision 2022, Role: Major Advisor
  • Outstanding Alumni Award in Academics, Research, and Innovation, Faculty of Allied Health Sciences, Thammasat University, 2026

Research Interests :

Precision medicine in oncology care

Research Summary :

My research centers on pharmacogenetics and pharmacogenomics, with a focus on understanding how genetic variation influences drug response and toxicity in the Thai population. From 2011 to 2017, I investigated the pharmacogenetics of irinotecan and its association with clinical toxicity. This was followed by studies between 2018 and 2020 examining the roles of UGT1A1 and SLCO1B1 polymorphisms in neonatal hyperbilirubinemia. Since 2019, my work has expanded to include the analysis of UGT1A1 variants (*80 and *28) and the pharmacogenetics of 5-fluorouracil in Thai colorectal cancer patients, aiming to support precision oncology. More recently, I have contributed to an international collaboration (Thailand–France, 2022–2023) investigating the pharmacogenomics of anticancer and immunosuppressive drugs, further strengthening the application of personalized medicine in clinical practice.